← Back to Search
A Phase II Study Of Intermittent Sunitinib Malate As Second-Line Therapy In Progressive Malignant Pleural Mesothelioma
A. Nowak, M. Millward, J. Creaney, R. Francis, I. Dick, A. Hasani, A. A. van der Schaaf, A. Segal, A. Musk, M. Byrne
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
Introduction: There is no accepted second-line therapy for patients with advanced malignant pleural mesothelioma (MPM), whose disease has progressed after first-line chemotherapy. The multitargeted tyrosine kinase inhibitor sunitinib malate targets several pathways overexpressed in mesothelioma. This phase II study assessed objective response to sunitinib and correlative biomarkers in patients with progressive pretreated MPM. Methods: Eligible patients had confirmed MPM, radiological progression after chemotherapy, Eastern Cooperative Oncology Group performance status 0 to 1, and measurable disease. Patients received oral sunitinib 50 mg daily for 28 of every 42 days. The primary endpoint was objective radiological response. Patients without prior pleurodesis had fluorodeoxyglucose positron emission tomographic response assessed by total glycolytic volume criteria. Correlative biomarkers included serum mesothelin, vascular endothelial growth factor (VEGF)-A, VEGF-C, interleukin-8, sVEGFR-2, sVEGFR-3, and s-kit. Results: Fifty-three patients received sunitinib between July 2006 and December 2009; 51 were assessable for response. Patients received a median of two cycles (range, 1–12); 40% required dose reduction. Fatigue was the most prominent toxicity. Six patients (12%) had a confirmed radiological partial response, 34 (65%) had stable disease, and 11 (22%) had progressive disease as best response. Six of 20 patients had a decrease in fluorodeoxyglucose positron emission tomographic total glycolytic volume of 15% or more. Median overall survival was 6.1 months, and median time to progression was 3.5 months. Correlative biomarkers did not predict treatment response. Conclusions: Sunitinib has activity in a subset of patients with pretreated MPM. Consideration should be given to different treatment schedules and examination of other biomarkers for further study of sunitinib in MPM.
This paper references
EXPRESSION OF PLATELET‐DERIVED GROWTH FACTOR (PDGF) AND PDGF RECEPTORS IN HUMAN MALIGNANT MESOTHELIOMA IN VITRO AND IN VIVO
A. Langerak (1996)
A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM)
C. Lee (2008)
A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC.
J. Van Meerbeeck (2004)
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307)
P. Jänne (2007)
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.
C. Porta (2010)
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles
K. Ikuta (2009)
Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo.
L. Metheny-Barlow (2001)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
J. Ebos (2007)
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
S. Novello (2009)
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
H. Kalantari (2009)
2nd, et al.; Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia
R Govindan (2005)
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis.
B. H. Kwek (2004)
Co-Expression of Vascular Endothelial Growth Factor and Its Receptor flt-1 in Malignant Pleural Mesothelioma
J. Koenig (2000)
c-Kit Is Not Expressed in Malignant Mesothelioma
A. Horvai (2003)
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
C. Porta (2006)
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
A. Zhu (2009)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
S. George (2009)
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced nonsmall cell lung cancer
S Novello (2009)
Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma
J. König (1999)
Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
A. Norden-Zfoni (2007)
Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors.
M. Versnel (1988)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
B. Schneider (2008)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
R. Wahl (2009)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
Dan Huang (2010)
FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate
AD Van den Abbele (2005)
Induction of Stem Cell Factor/c-Kit/Slug Signal Transduction in Multidrug-resistant Malignant Mesothelioma Cells*
A. Catalano (2004)
The Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice
Q. Li (2007)
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
F. Demirag (2005)
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2006)
The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
K. Steffensen (2010)
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
J. Christensen (2007)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
S. Deprimo (2007)
Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.
J. Nutt (2009)
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
B. Escudier (2009)
A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM).
J. Dowell (2009)
SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma.
L. Garland (2009)
Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma
A. Yasumitsu (2010)
This paper is referenced by
KAT 5 ( Tip 60 ) is a potential therapeutic target in malignant pleural mesothelioma
S. Cregan ()
Nintedanib : new treatment for malignant pleural mesothelioma
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review
O. Abdel-Rahman (2015)
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
Pavel A. Levin (2017)
A new standard for malignant pleural mesothelioma
Aneel Bhangu (2016)
[Malignant pleural mesothelioma: new aspects of medical therapy].
S. Kurz (2014)
Advances in treatment of mesothelioma
C. Maggioni (2016)
New directions in mesothelioma treatment
Anna K. Nowak (2015)
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
J. Stevenson (2013)
Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
H. Taghizadeh (2020)
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma
M. O. Jamil (2017)
alignant pleural mesothelioma
F. Honeyball (2013)
Genomic Landscape of Malignant Mesotheliomas.
S. Kato (2016)
The Role of Surgery in Malignant Pleural Mesothelioma
Levon Toufektzian (2015)
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer
Massimo Di Maio (2017)
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.
V. Prasad (2014)
Measuring Malignant Pleural Mesothelioma
A. Nowak (2019)
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
A. Nowak (2013)
Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy
F. Grosso (2018)
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.
A. Mansfield (2014)
Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma.
M. Disselhorst (2020)
The Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma
E. Pulford (2017)
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
W. Buikhuisen (2016)
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
A. Tsao (2019)
Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?
D. Signorelli (2016)
Mesothelioma: is chemotherapy alone a thing of the past?
A. Bibby (2020)
Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
M. Zauderer (2017)
Mesothelioma treatment: Are we on target? A review
B. Hiddinga (2015)
A new standard for malignant pleural mesothelioma
M. Zauderer (2016)See more